Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/18/2019 02/19/2019 02/20/2019 02/21/2019 02/22/2019 Date
90.04(c) 90.04(c) 90.68(c) 90.64(c) 90.34 Last
2 829 030 3 584 145 4 065 498 3 873 463 715 080 Volume
-0.04% 0.00% +0.71% -0.04% -0.33% Change
More quotes
Financials (USD)
Sales 2019 53 532 M
EBIT 2019 14 099 M
Net income 2019 8 856 M
Debt 2019 14 792 M
Yield 2019 3,28%
Sales 2020 56 002 M
EBIT 2020 15 143 M
Net income 2020 9 864 M
Debt 2020 10 826 M
Yield 2020 3,42%
P/E ratio 2019 22,38
P/E ratio 2020 20,03
EV / Sales2019 4,59x
EV / Sales2020 4,32x
Capitalization 231 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (67.2%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
02/28 | 04:00amShareholder meeting
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
02/20NOVARTIS : Beximco Pharmaceuticals Acquires U.S. New-Drug Applications From Sand..
DJ
02/19INDIVIOR : Sandoz Launches New Generic to Treat Opioid Dependence
DJ
02/13NOVARTIS : receives FDA approval for Egaten® for the treatment of fascioliasis, ..
GL
02/13CLINIGEN : agrees to buy U.S. rights to Novartis' cancer drug Proleukin
RE
02/12GLAXOSMITHKLINE : Mylan launches Advair generic at one-third price
RE
02/11RECRO PHARMA : in New Supply Agreement with Novartis
DJ
02/07GLOBAL MARKETS LIVE : General Motors, Sonos, Chipotle Mexican Grill, Publicis ....
02/07NOVARTIS : CEO lauds Trump administration plan to overhaul rebates
RE
02/06NOVARTIS INDIA : Q3 profit dips 31% to Rs 13 crore
AQ
02/05NOVARTIS : Alcon eye-care unit to enter Swiss index after spin off
RE
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 2018
Technically solid
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
02/21BAYER : DowDuPont wins final OK for global launch of new GMO soybeans
RE
02/21GLOBAL MARKETS LIVE : J&J, UBS, YouTube, Standard Chartered…
02/21MERCK AND : to Buy Immune Design for $5.85 A Share
DJ
02/21JOHNSON & JOHNSON : J&J Gets Subpoenas Related To Talc
DJ
02/21BRISTOL MYERS SQUIBB : Starboard Nominates Bristol Board Members
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 94,4 $
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.85%231 004
JOHNSON & JOHNSON5.66%365 688
PFIZER-3.32%244 760
ROCHE HOLDING LTD.13.68%237 660
MERCK AND COMPANY3.95%206 548
ELI LILLY AND COMPANY6.00%129 936